...
Product Theater – Let’s Talk About an Option for Your Patients with Challenging Manifestations of Psoriasis
November 23, 2019

Faculty: Michael Shane Chapman, MD Dr. Michael Chapman presented the afternoon product theater reviewing Otezla (apremilast). Otezla is indicated for the treatment of adult patients with active psoriatic arthritis and patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. He mentioned we should approach “psoriasis as a systemic condition …

...
Do PDE4 Inhibitors Work as Treatment for Hidradenitis Suppurativa?
January 17, 2019

Hidradenitis suppurativa (HS) is a chronic, autoinflammatory skin disorder that presents with painful, itchy, inflamed nodules, and abscesses. It affects about 1% of the population, more frequently in females, often first appearing in adolescence. First-line therapies include anti-inflammatory oral antibiotics, but more recently treatment with the biologic adalimumab has demonstrated clinically significant improvement in the …

...
SDPA Fall 2018 | Product Theater | Are Your Topical Patients Systemic-Ready? An Oral Treatment Option for Moderate to Severe Plaque Psoriasis
November 3, 2018

At the first product theater on day 3 of the 16th Annual Fall Dermatology Conference, Dr. Firas Hougeir shared his extensive knowledge and experience in the treatment of patients with psoriasis with his lecture entitled Are Your Topical Patients Systemic-Ready? An Oral Treatment Option for Moderate to Severe Plaque Psoriasis. Dr. Hougeir started his lecture …